Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 23

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 23
---
 could involve substantial restrictions on activities and creditors could seek a pledge
of some or all of our assets. We have not identified potential sources for such financing that we will require, and we do not have commitments
from any third parties to provide any future debt financing.

If we are unable to raise capital when needed
on commercially reasonable terms, we could be forced to delay, reduce or eliminate our research and development for our product candidates
or any future commercialization efforts or ultimately cease operations. Any of these events could significantly harm our business, financial
condition and prospects.

We anticipate that we can successfully develop the acquired business of LipoVation resulting from the closing of the Share Exchange. However, if we fail to comply with LipoVation’s contractual obligations under the Yissum License Agreements, we could lose license rights that may be necessary for developing our Nano-Liposomal Particles (NLP)-based medicines based therapeutic products.

The exclusive license granted to LipoVation by
Yissum under the Yissum License Agreements imposes various development, commercialization, funding, royalty, diligence, sublicensing,
insurance and other obligations on us. Our obligations under the Yissum License Agreements include, without limitation:

| ● | royalty payments; |

| ● | annual maintenance fees; |

<div align='center'>10</div>

| ● | annual progress reports; |

| ● | milestone payments; |

| ● | maintaining insurance coverage; |

| ● | paying fees related to prosecution, maintenance and enforcement of patent rights; and |

| ● | undertaking diligent efforts to develop and to introduce therapeutic products into the commercial market as soon as practicable. |

These obligations subject us to the risk that
we may lose such license if we breach any of our material obligations described above and fail to remedy such material breach within 90
days (provided that such breach is curable within 90 days), or if we become bankrupt or insolvent, or if our business is placed in the
hands of a receiver, assignee or trustee, because Yissum has the right to terminate this license pursuant to the terms of the Yissum License
Agreements. This could result in inability of the Company to develop, manufacture and sell products that are covered by the licensed technology
pursuant to the Yissum License Agreements (the “Licensed Technology”) and could also result in competitors gaining access
to Licensed Technology.

The Israeli Contract Law (Remedies for Breach
of Contract) 1970